Agile Therapeutics Announces FDA Extension of Twirla NDA Review Period

5 years ago

by David Miller

951 Views

Written by David Miller

PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!